Carotid Artery Thickness in HIV Infected and Uninfected Adults
Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults: A Pilot Study
Studieoversikt
Status
Detaljert beskrivelse
Determination of clinical, lipid, and non-lipid risk factors has been the traditional approach for gauging an individual's risk for coronary artery disease (CAD). However, the IMT test, which uses sound waves to measure the thickness of the carotid artery, has been found to diagnose CAD and predict a person's risk for heart disease as well as or better than lipid and non-lipid risk factors. This study will use the IMT test to see if anti-HIV treatment and HIV infection affect a patient's risk of developing atherosclerosis (hardening of the arteries) by comparing carotid artery thickness among HIV infected adults taking PIs, HIV infected adults not taking PIs, and HIV uninfected adults.
There are 3 groups in this study. Group 1 will comprise HIV infected participants currently taking a PI-containing regimen. Group 2 will comprise HIV infected participants who are not taking PIs. Group 3 will comprise HIV uninfected participants. At each site, participants will be enrolled by "triads" consisting of an individual from each group. Each member of the triad will be closely matched by gender, age, smoking and menopausal status, race, and normal or hypertensive blood pressure. All 3 members of the triad must be identified before participants are registered to the study.
All participants will visit the clinic at Weeks 1, 24, 48, 72, 96, and 144 (3 years). At each visit, participants will have a physical exam, medical history and waist/hip ratio assessment, blood collection, and an IMT test. The absolute value for carotid IMT will be compared among the 3 groups. Viral load and CD4 counts will also be measured in Group 1 and 2 participants.
Studietype
Registrering
Kontakter og plasseringer
Studiesteder
-
-
California
-
Harbor City, California, Forente stater, 90710
- Kaiser Foundation Hosp
-
Los Angeles, California, Forente stater, 90095
- UCLA CARE Ctr
-
Los Angeles, California, Forente stater, 900331079
- Univ of Southern California / LA County USC Med Ctr
-
Los Angeles, California, Forente stater, 90027
- Kaiser Permanente LAMC
-
San Diego, California, Forente stater, 92103
- Univ of California, San Diego
-
Torrance, California, Forente stater, 90502
- Harbor UCLA Med Ctr
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96816
- Univ of Hawaii
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- Univ of Minnesota
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Univ of Pennsylvania
-
-
Washington
-
Seattle, Washington, Forente stater, 98104
- Univ of Washington
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria for Group 1
- HIV infected
- Have taken at least 1 PI continuously for 2 or more years and are currently taking at least 1 PI. Stopping therapy for 4 weeks or less for management of side effects or to change therapy is allowed.
- Viral load of 10,000 copies/ml or less
Inclusion Criteria for Group 2
- HIV infected
- Not currently receiving PIs or have not taken PIs in at least 3 months
- Not planning to initiate PI therapy in the few months following study entry
- Viral load of 10,000 copies/ml or less
- If not currently on anti-HIV treatment, must have been on treatment for at least 6 months in the past
Inclusion Criteria for Group 3
- HIV uninfected
Exclusion Criteria for All Groups
- Diabetes or current use of oral medications for diabetes
- Kidney disease
- ALT or AST greater than 2.5 times the upper limit of normal
- Hypothyroidism
- Family history (parents, brothers, sisters, or children) of heart attacks before age 55 in males and age 65 in females
- Alcohol or drug abuse
- Pregnant or plan to become pregnant during the study
- Body mass index (BMI) greater than 30
- Systemic chemotherapy or radiation therapy
- Systemic steroids (prednisone or equivalent) at doses greater than 5 mg/day for more than 30 consecutive days
- History of coronary heart disease or stroke (including chest pain, heart attack, or abnormal stress test)
- Uncontrolled hypertension
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Judith S. Currier, MD, MSc, University of California, Los Angeles
- Studiestol: Howard N. Hodis, MD, Atherosclerosis Research Unit, University of Southern California
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs. 2002;2(2):91-106. doi: 10.2165/00129784-200202020-00003.
- Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003 Aug;22(2):89-99. doi: 10.1016/s0924-8579(03)00115-8.
- Barbaro G. HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc Res. 2003 Oct 15;60(1):87-95. doi: 10.1016/s0008-6363(02)00828-3.
- Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003 Nov 21;17(17):2479-86. doi: 10.1097/00002030-200311210-00010.
- Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J. 2004 Jan;147(1):55-9. doi: 10.1016/j.ahj.2003.07.007.
- Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN; AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005 Jun 10;19(9):927-33. doi: 10.1097/01.aids.0000171406.53737.f9.
Studierekorddatoer
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ACTG A5078
- AACTG A5078
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .